GUAVA PERSONAL CELL ANALYSIS-96 SYSTEM: CANCER

这个子项目是利用由NIH/NCRR资助的共享仪器赠款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是用于拨款的，而不一定是用于调查人员的机构。描述(由申请人提供)：本申请请求支持番石榴EasyCyte，该系统允许对样本进行细胞计数和活力、蛋白质表达、多聚天冬氨酸酶、TUNEL和96孔格式的细胞周期分析。虽然这些分析大多可以在单个实验室小规模进行，但它们既耗时又昂贵，而且结果往往是可变的和取决于用户的。集中这些研究并为各种细胞反应的高通量分析提供最先进的设备的机会将最大限度地减少成本和时间，并最大限度地提高产量。目前，福克斯·蔡斯癌症中心没有具有类似能力的仪器，也没有资金用于这种仪器。虽然代表番石榴EasyCyte计划用户的11个由NIH资助的实验室的具体项目各不相同，但它们都有一个共同的目标，即确定小分子、药物或基因表达变化对癌细胞生物学的影响，特别是细胞周期和细胞凋亡的调控途径。所要求的仪器将被安置在福克斯·蔡斯癌症中心的翻译研究核心设施中，并进行管理和维护，作为我们新的翻译计划的一部分，该中心正在快速扩张。该基金的主要目标是支持基础科学家和临床研究人员之间的互动产生的新的转化性研究倡议，并协助开发癌症的新疗法。鉴于我们实验室的规模相对较小(平均为4.5)，除非这个中央设施增加我们有限的人力，否则大多数这些研究都是不可行的。收购这一仪器将是朝着提供必要的高通量、集中化支持迈出的关键的第一步，以承担本提案中列出的NIH研究人员的临床相关项目，以及随着更多的研究人员意识到这一仪器的杰出能力而肯定会出现的许多新倡议。

This subproject is one of many research subprojects utilizing the resources provided by a Shared Instrumentation Grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the grant, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): This application requests support for a Guava EasyCyte, a system that allows samples to be assayed for cell count and viability, protein expression, Multicaspase, TUNEL and the cell cycle in a 96-well format. Although most of these assays can be performed on a small scale in individual laboratories, they are time-consuming and expensive, and results are often variable and user-dependent. The opportunity to centralize these studies and provide state-of-the-art equipment for high-throughput assays of a variety of cell responses will minimize cost and time, and maximize output. At present there is no instrument with similar capabilities at Fox Chase Cancer Center, nor is there funding available for such instrumentation. While the specific projects of the 11 NIH funded laboratories that represent the projected users of the Guava EasyCyte vary, they share the common goal of determining the effects of small molecules, pharmaceuticals or the alteration of gene expression on cancer cell biology, particularly the regulatory pathways of the cell cycle and apoptosis. The instrument requested will be housed, managed and maintained in the Translational Research Core Facility of Fox Chase Cancer Center, which is undergoing rapid expansion as part of our new Translational Initiative. The primary goal of the Facility is to support new translational research initiatives that arise from interactions among basic scientists and clinical investigators and to assist in the development of novel therapies for cancer. Given the relatively small size of our laboratories (avg.=4.5), most of these studies would not be feasible unless our limited manpower was augmented by this centralized facility. Acquisition of this instrument will provide a first critical step toward providing the high-throughput, centralized support necessary to undertake the clinically-relevant projects of the NIH investigators listed in this proposal, as well as the many new initiatives that are sure to arise as additional investigators become aware of the outstanding capabilities of this instrument.